PharmiWeb1d
STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
STADA, a leading healthcare and pharmaceutical company in Consumer Healthcare, Generics and Specialty pharmaceuticals, continued its profitable growth journey in 2024. STADA again outperformed the ...
Business Review4d
STADA’s growth journey continues in 2024 – Significant increase in sales and profits
Pharma - STADA, a leading healthcare and pharmaceutical company in Consumer Healthcare, Generics and Specialty ...
thecardiologyadvisor.com5d
Rivaroxaban: Optimal Direct Oral Anticoagulant for Upper Gastrointestinal ESD
In patients undergoing upper gastrointestinal endoscopic submucosal dissection, risk for ischemic stroke was lower with rivaroxaban than with dabigatran. Rivaroxaban was associated with a lower risk ...
National Institute for Health and Care Excellence6d
Published guidance, NICE advice and quality standards
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...